Middle East & Africa Infectious Disease In vitro Diagnostics Market Size and Forecast (2021 - 2031), Regional Share, Trend, and Growth Opportunity Analysis

The Middle East & Africa Infectious Disease In Vitro Diagnostics (IVD) Market is projected to experience significant growth, with an expected market size of approximately US$ 2,391.5 million by 2031, up from US$ 1,526.0 million in 2024. This growth translates to a compound annual growth rate (CAGR) of 6.7% from 2025 to 2031.

### Executive Summary
The IVD market for infectious diseases in the Middle East & Africa, particularly in key countries such as the UAE, Saudi Arabia, and South Africa, is poised for substantial expansion in the coming years. This growth is driven by several factors, including advancements in healthcare infrastructure, supportive government initiatives, and enhanced international collaborations aimed at improving diagnostic capabilities. Saudi Arabia and the UAE are leading this growth trajectory by investing heavily in healthcare and technological advancements. Meanwhile, South Africa is witnessing market development through the introduction of new products, public-private partnerships, and government support for healthcare innovation.

The rising incidence of infectious diseases and the demand for reliable, cost-effective, and rapid IVD solutions are awakening the region to the critical importance of diagnostics. The ongoing modernization of the healthcare sector and a focus on early disease detection are expected to further accelerate the adoption of IVD technologies across the region.

### Market Segmentation
The Middle East & Africa Infectious Disease IVD Market is segmented by application and end-user. In terms of applications, the market includes categories such as HIV/AIDS, Tuberculosis, Hepatitis B and C, Malaria, and others. Notably, Hepatitis B and C are projected to hold the largest market share in 2024.

By end-user, the market is divided into Hospitals and Clinics, Diagnostic Laboratories, Blood Banks, and others, with Hospitals and Clinics also expected to dominate the market share in 2024.

### Market Outlook
According to the World Health Organization (WHO), tuberculosis (TB) affects around 10 million people globally each year, resulting in approximately 1.5 million deaths annually. Despite being preventable and treatable, TB remains one of the leading infectious disease killers worldwide, particularly in low- and middle-income countries. The prevalence of HIV is also on the rise, with an estimated 39.9 million individuals living with the virus as of the end of 2023. This epidemic varies significantly across different regions, highlighting the urgent need for effective diagnostic solutions.

Additionally, the increasing incidence of fungal infections poses a significant health risk, with over 80 million people at high risk of developing such diseases annually. The Global Action Fund for Fungal Infections (GAFFI) reports that approximately 6.55 million patients develop life-threatening fungal infections each year, leading to around 3.75 million deaths. This alarming trend underscores the critical need for in vitro diagnostics to facilitate early detection and treatment of infectious diseases.

The rising prevalence of infectious diseases such as HIV, hepatitis, tuberculosis, and influenza is driving demand for rapid and accurate diagnostic solutions. Innovations in molecular diagnostics, improved point-of-care testing, and a greater emphasis on early detection and disease surveillance are collectively propelling the adoption of IVD methodologies across both developed and emerging healthcare markets.

### Country Insights
The market is further segmented by country, with significant contributions from South Africa, Saudi Arabia, the UAE, and the Rest of the Middle East & Africa. Saudi Arabia is expected to hold the largest market share in 2024, benefiting from increased healthcare investments aligned with the Kingdom's Vision 2030 initiative. Health expenditure in Saudi Arabia is projected to grow by 3% annually from 2022 to 2025, aimed at enhancing public hospitals, clinical laboratories, and modern diagnostic facilities.

The demand for IVD solutions, particularly for infectious diseases and oncology, is accelerating due to rising investments from both public and private sectors. Vision 2030 is also facilitating a strategic decentralization of healthcare services, shifting diagnostic capabilities from tertiary hospitals to primary and community care centers, thereby improving access and enabling earlier detection of critical health conditions.

Despite these advancements, challenges remain, particularly in diagnostic coverage for essential infectious diseases. For instance, only 10.45% of hepatitis B cases and 43% of hepatitis C cases were diagnosed in 2022, indicating a significant gap in healthcare delivery.

### Key Players
Key players in the Middle East & Africa Infectious Disease IVD Market include Abbott Laboratories, F. Hoffmann-La Roche Ltd, Sysmex Corp, bioMerieux SA, Bio-Rad Laboratories Inc, QIAGEN NV, Bruker Corp, QuidelOrtho Corp, Becton, Dickinson and Co, and Danaher Corp. These companies are actively pursuing strategies such as expansion, product innovation, and mergers and acquisitions to enhance their market presence and offer innovative solutions to consumers.